Page last updated: 2024-09-26

5,6-didehydrosparteine

Description

5-dehydrosparteine: urinary metabolite of sparteine; RN given refers to (7S-(7alpha,14alpha,14abeta))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5,6-didehydrosparteine : A quinolizidine alkaloid obtained by formal dehydrogenation at the 5,6-position of sparteine. It is a metabolite of sparteine found in human urine and plasma. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID160614
CHEBI ID143195
SCHEMBL ID11352489
MeSH IDM0130372

Synonyms (11)

Synonym
5-dehydrosparteine
5,6-didehydrosparteine
CHEBI:143195
2130-67-8
(7s,14s,14as)-1,3,4,7,9,10,11,13,14,14a-decahydro-2h,6h-7,14-methanodipyrido[1,2-a:1',2'-e][1,5]diazocine
5,6-ddhsp
7,14-methano-2h,6h-dipyrido(1,2-a:1',2'-e)(1,5)diazocine, 1,3,4,7,9,10,11,13,14,14a-decahydro-, (7s-(7alpha,14alpha,14abeta))-
SCHEMBL11352489
5,6-dehydrospartein
DTXSID20943804
(1s,9s,10s)-7,15-diazatetracyclo[7.7.1.02,7.010,15]heptadec-2-ene

Roles (1)

RoleDescription
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
quinolizidine alkaloid
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
organic heterotetracyclic compound
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (63.64)18.7374
1990's3 (27.27)18.2507
2000's1 (9.09)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (9.09%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research Highlights

Pharmacokinetics (1)

ArticleYear
Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers.
British journal of clinical pharmacology, Volume: 52, Issue: 6
2001
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (1)

ArticleYear
Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers.
British journal of clinical pharmacology, Volume: 52, Issue: 6
2001
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (1)

ArticleYear
Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians.
Clinical pharmacology and therapeutics, Volume: 37, Issue: 5
1985
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]